课题基金 / 基金详情

CD22 Regulation of B Lymphocyte Function and Survival

CD22 Regulation of B Lymphocyte Function and Survival
CD22 对 B 淋巴细胞功能和存活的调节
批准号:
7226972
负责人:
THOMAS F TEDDER
金额:
$24.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-05-01 至 2008-04-30

项目摘要

项目成果

THOMAS F TEDDER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): B lymphocytes are the central mediators of humoral immunity. Aberrant B cell function contributes to many autoimmune diseases and age-related defects in humoral immunity, with malignant B lymphocytes representing the primary cell type in leukemia and lymphoma. B cell function is regulated through cell-surface molecules that generate transmembrane signals, regulate intercellular communication, and direct lymphocyte localization within tissues. Other than the B cell antigen receptor (BCR) complex, relatively very little is known about the function and signal transduction pathways of most B cell-surface proteins. The aim of these studies is to examine the function of CD22, a B lymphocyte-specific cell-surface receptor. CD22 is a lectin-like member of the immunoglobulin superfamily that functions as an adhesion molecule for diverse sialylated cell-surface and soluble ligands. Ligand binding by CD22 may regulate both positive and negative effects of transmembrane signals generated through the BCR and CD19. Moreover, genetic alterations in CD22 ligand binding activity, structure, or expression may contribute to autoimmunity by altering its regulatory interactions with SHP 1 and SHIP, potent intracellular phosphatases. We propose that adhesion receptor function of CD22 regulates transmembrane signals and BCR-induced cell death in peripheral B cells. There are four specific aims designed to test this hypothesis and to further determine how CD22 regulates B cell function. In specific aim 1, the functional significance and functional consequences of CD22 ligand binding will be assessed in vivo by analyzing new lines of mice, which express mutated cell-surface CD22 molecules that lack ligand-binding activity. In specific aim 2, we will use B cells from CD22-deficient and -mutant mice to dissect how CD22 regulates B cell survival. Specific Aim 3 will assess CD22 intracellular signal transduction pathways. In specific aim 4, the role of CD22 in the development of an autoimmune repertoire will be assessed and we will determine whether CD22 engagement influences the age of onset or severity of autoantibody production. Since CD22 provides an important regulatory checkpoint for adjusting humoral immune responses, understanding CD22 function may provide mechanisms for modulating humoral immunity and the treatment of B cell abnormalities leading to immunodeficiency, autoimmunity or malignancy.
期刊论文(34)
专著(0)
科研奖励(0)
会议论文
B-lymphocyte depletion for the treatment of multiple sclerosis: now things really get interesting.
B 淋巴细胞去除治疗多发性硬化症:现在事情真的变得有趣了。
DOI: 10.1586/14737175.9.3.309
发表时间: 2009
期刊: Expert review of neurotherapeutics
影响因子: 4.3
作者: [Matsushita,Takashi, Tedder,ThomasF]
通讯作者: Tedder,ThomasF
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.
在抗 CD20 抗体免疫治疗期间,先天单核吞噬细胞网络通过 Fc 受体依赖性机制耗尽 B 淋巴细胞。
DOI: 10.1084/jem.20040119
发表时间: 2004-06-21
期刊: The Journal of experimental medicine
影响因子: --
作者: [Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF]
通讯作者: Tedder TF
DOI: 10.1084/jem.20052283
发表时间: 2006-03-20
期刊: JOURNAL OF EXPERIMENTAL MEDICINE
影响因子: 15.3
作者: [Hamaguchi, Y, Xiu, Y, Komura, K, Nimmerjahn, F, Tedder, TF]
通讯作者: Tedder, TF
DOI: 10.4049/jimmunol.0901719
发表时间: 2010-05-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Nakashima H, Hamaguchi Y, Watanabe R, Ishiura N, Kuwano Y, Okochi H, Takahashi Y, Tamaki K, Sato S, Tedder TF, Fujimoto M]
通讯作者: Fujimoto M
15
    Regulatory B cell inhibition of immune responses to pathogens
    Regulatory B cell inhibition of immune responses to pathogens
    Regulatory B10 Cells in Autoimmune Arthritis
    • 批准号:
      7688871
    • 项目类别:
    • 资助金额:
      $77.67万
    • 财政年份:
      2009
    • 负责人:
      THOMAS F TEDDER
    • 依托单位:
    Regulatory B cell inhibition of immune responses to pathogens
    海外基金